Abstract
Purpose: To correlate p53 and ErbB receptors status with disease-free survival (DFS) and overall survival (OS) in locally advanced breast cancer. Patients and Methods: Sixty patients were included in a single-center, open-label, phase II trial (1998-2003). Analysis of Erb receptors and p53 status and estrogen receptor/progesterone receptor data were available for 33 patients. Neoadjuvant epirubicin 75 mg/m2 and paclifaxel 175-200 mg/m2 were administered every 21 days. The patients underwent surgery and radiation therapy and adjuvant chemo/hormonotherapy. Results: Approximately two thirds of the patients demonstrated overexpression of ErbB receptors and had mutant p53 overexpression. The disease recurred in 11133 patients and 7 died (median follow-up 56 months). Detrimental effects on OS were established in cases of combined defective p53 expression and ErbB1-ErbB3 heterodimeric receptor overexpression. In contrast, normal p53 together with the same overexpressed heterodimeric combination of ErbB receptors showed no statistically significant effect. Conclusion: In terms of the clinical impact of combinations of ErbB receptors with or without mutant p53, only the overexpressed various ErbBl-ErbB3 dimeric combinations and the ErbB1/ErbB2/ErbB3 triplet combination with mutated p53 were related to a significantly poorer outcome. This observation may help in the development of new strategies required for blocking these molecular pathways and improving the outcome of patients with locally advanced breast cancer.
Original language | English |
---|---|
Pages (from-to) | 3147-3152 |
Number of pages | 6 |
Journal | Anticancer Research |
Volume | 28 |
Issue number | 5 B |
State | Published - Sep 2008 |
Keywords
- Breast
- Epirubicin
- Erb family
- Neoadjuvant chemotherapy
- P53
- Taxol